Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernt Johan von Scholten

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Nephron Extra|October 23, 2014
Urinary alpha- and pi-glutathione s-transferases in adult patients with type 1 diabetesBernt Johan von Scholten, Simone Theilade, Maria Lajer, et al.
Frontiers in Physiology|October 7, 2022
The potential of glucagon-like peptide-1 receptor agonists in heart failureFrederik Flindt Kreiner, G Kees Kornelis Hovingh, Bernt Johan von Scholten
Current Obesity Reports|October 4, 2016
Global Changes in Food Supply and the Obesity EpidemicEmilie H Zobel, Tine W Hansen, Peter Rossing, et al.
Current Opinion in Endocrinology, Diabetes, and Obesity|June 8, 2021
Current state of antigen-specific immunotherapy for type 1 diabetesFrederik Flindt Kreiner, Bernt Johan von Scholten, Ken Coppieters, et al.
Communications Medicine|May 23, 2022
Insulin at 100: still central in protein-based therapy for chronic diseasePeter Kurtzhals, Bernt Johan von Scholten, Frederik Flindt Kreiner, et al.
Therapeutic Advances in Endocrinology and Metabolism|July 25, 2022
The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practiceBernt Johan von Scholten, Frederik Flindt Kreiner, Søren Rasmussen, et al.
Aging Cell|May 16, 2023
Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentialsFrederik Flindt Kreiner, Bernt Johan von Scholten, Peter Kurtzhals, et al.
Current Pharmaceutical Design|June 24, 2017
Trimethylamine N-oxide (TMAO) as a New Potential Therapeutic Target for Insulin Resistance and CancerJens Oellgaard, Signe Abitz Winther, Tobias Schmidt Hansen, et al.
Journal of Diabetes and Its Complications|May 4, 2015
Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetesBernt Johan von Scholten, Tine Willum Hansen, Jens Peter Goetze, et al.
Diabetologia|February 17, 2021
Current and future therapies for type 1 diabetesBernt Johan von Scholten, Frederik F Kreiner, Stephen C L Gough, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Nephron Extra|October 23, 2014
Urinary alpha- and pi-glutathione s-transferases in adult patients with type 1 diabetesBernt Johan von Scholten, Simone Theilade, Maria Lajer, et al.
Frontiers in Physiology|October 7, 2022
The potential of glucagon-like peptide-1 receptor agonists in heart failureFrederik Flindt Kreiner, G Kees Kornelis Hovingh, Bernt Johan von Scholten
Current Obesity Reports|October 4, 2016
Global Changes in Food Supply and the Obesity EpidemicEmilie H Zobel, Tine W Hansen, Peter Rossing, et al.
Current Opinion in Endocrinology, Diabetes, and Obesity|June 8, 2021
Current state of antigen-specific immunotherapy for type 1 diabetesFrederik Flindt Kreiner, Bernt Johan von Scholten, Ken Coppieters, et al.
Communications Medicine|May 23, 2022
Insulin at 100: still central in protein-based therapy for chronic diseasePeter Kurtzhals, Bernt Johan von Scholten, Frederik Flindt Kreiner, et al.
Therapeutic Advances in Endocrinology and Metabolism|July 25, 2022
The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practiceBernt Johan von Scholten, Frederik Flindt Kreiner, Søren Rasmussen, et al.
Aging Cell|May 16, 2023
Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentialsFrederik Flindt Kreiner, Bernt Johan von Scholten, Peter Kurtzhals, et al.
Current Pharmaceutical Design|June 24, 2017
Trimethylamine N-oxide (TMAO) as a New Potential Therapeutic Target for Insulin Resistance and CancerJens Oellgaard, Signe Abitz Winther, Tobias Schmidt Hansen, et al.
Journal of Diabetes and Its Complications|May 4, 2015
Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetesBernt Johan von Scholten, Tine Willum Hansen, Jens Peter Goetze, et al.
Diabetologia|February 17, 2021
Current and future therapies for type 1 diabetesBernt Johan von Scholten, Frederik F Kreiner, Stephen C L Gough, et al.
Pageof 5